Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions

BACKGROUND: Amplivant is a molecularly optimized Toll-like receptor 2 ligand that can be covalently conjugated to tumor peptide antigens. In preclinical models, amplivant-adjuvanted synthetic long peptides (SLPs) strongly enhanced antigen presentation by dendritic cells, T cell priming and induction...

Descripción completa

Detalles Bibliográficos
Autores principales: Speetjens, Frank M, Welters, Marij J P, Slingerland, Marije, van Poelgeest, Mariette I E, de Vos van Steenwijk, Peggy J, Roozen, Inge, Boekestijn, Sanne, Loof, Nikki M, Zom, Gijs G, Valentijn, A Rob P M, Krebber, Willem-Jan, Meeuwenoord, Nico J, Janssen, Catharina A H, Melief, Cornelis J M, van der Marel, Gijs A, Filippov, Dmitri V, van der Burg, Sjoerd H, Gelderblom, Hans, Ossendorp, Ferry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582304/
https://www.ncbi.nlm.nih.gov/pubmed/36261215
http://dx.doi.org/10.1136/jitc-2022-005016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582304/
https://www.ncbi.nlm.nih.gov/pubmed/36261215
http://dx.doi.org/10.1136/jitc-2022-005016

Ejemplares similares